Vertex Pharmaceuticals (VRTX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$540.00+1.95%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put VRTX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 10% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 14%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look high — the market is pricing in about 60% growth a year, above the roughly 14% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskVertex’s cystic fibrosis franchise and broader product reach underpin the growth case. Revenue growth accelerated from 8% to 12% year over year, with Q2 FY2026 earnings beating consensus. VRTX trades at 29× P/E versus a 21× peer median. The market is pricing in more growth than our forecast. The premium is vulnerable if cystic fibrosis expansion disappoints; our model puts next-quarter miss probability near 25%. Peer multiples imply a price about 60% below where it trades. Our read remains intact, and this read is provisional.
Trailing returns as of 2026-10-29. VRTX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 33 analysts currently covering VRTX (as of Oct 2026).
Based on 14 Wall Street analysts offering 12-month price targets for VRTX in the last 4 months.
Continue this research
Compare VRTX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| VRTX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put VRTX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Expand cystic fibrosis (CF) product reach
Price target cut indicates concerns about CF product outlook.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $540.00
The last 12 months of price, then the range of analyst 12-month targets from today’s $540.00.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Expand cystic fibrosis (CF) product reach
Positive data supports expansion of CF product reach.
Advances: Expand cystic fibrosis (CF) product reach
Positive trial data supports CF product expansion.
Acquisition expands growth potential beyond current CF focus.
Acquisition enhances product pipeline and growth potential.
Threatens: Expand cystic fibrosis (CF) product reach
Lupin's ruling impacts Vertex's CF product reach.
Advances: Expand cystic fibrosis (CF) product reach
Rival drug failure enhances Vertex's CF product position.
Advances: Expand CF product reach
Rival drug failure enhances Vertex's CF product reach.
